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The Duffy Blood Group System
Fatima A. Aldarweesh
Abstract
The Duffy group system includes six known antigens that reside on a glycopro-
tein which acts as a receptor for chemokines. It is also a receptor for some malaria 
species. There are significant racial variations in expression of Duffy antigens. 
Approximately 68% of Blacks lack both Fya and Fyb antigens. Individuals with this 
unique phenotype are resistant to two malaria species. Antibodies formed against 
the Duffy antigens are of IgG subclass and are clinically significant as they can be 
implicated in acute and delayed hemolytic transfusion reactions as well as hemo-
lytic disease of fetus and newborn. Patients who form anti-Fya or anti-Fyb must 
receive antigen negative blood units in the future.
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1. Introduction
The Duffy blood group system, ISBT number 008/symbol (FY), was published for 
the first time in 1950 when anti-Fya was identified in a suspected hemolytic transfu-
sion reaction in a 43-year-old patient with hemophilia who received 3 packed red blood 
cell (PRBC) units for treatment of spontaneous bleeding and who developed jaundice 
1 day after transfusion [1, 2]. Approximately, 1 year later, anti-Fyb was discovered in a 
postpartum blood sample from a patient who gave birth to her third child [3].
Chromosome 1 has both FY and RH gene loci. The FY locus is located on the 
long arm at position 1q22-q23 where it consists of two exons distributed over 1.5 kbp 
of gDNA, whereas RH resides on the short arm. The Duffy system is N-glycosylated 
multi-pass transmembrane glycoprotein (Figure 1) [4] also known as the atypical 
chemokine receptor 1 (ACKR1, CD234). The protein is composed of 336 amino 
acids. There are two possible Duffy mRNAs which are translated from the Duffy 
antigen gene, a less abundant α form (338 amino acids) and a major β form (336 
amino acids) which differ by 2 amino acids in the N-terminus. Approximately 
6000–13,000 copies of the Duffy protein are found on the surface of RBCs [5].
The Duffy blood group includes six known antigens that differ by amino acid 
sequence. The Duffy antigen prevalence varies between racial groups.
ACKR1 (previously known as DARC) is a receptor for a variety of chemokines, 
including interleukin-8, monocyte chemotactic protein-1, and melanoma growth 
stimulatory activity. Also, this glycoprotein is a receptor for Plasmodium vivax and 
Plasmodium knowlesi; thus red cells with Fy(a-b-) phenotype are resistant to inva-
sion by these malarial species. Antibodies formed against the Duffy antigens show a 
dosage effect and are a cause of both hemolytic transfusion reactions and hemolytic 
disease of fetus and newborn. The Duffy protein is also found on the endothelial 
cells of capillary and postcapillary venules, the epithelial cells of kidney collecting 
ducts, lung alveoli, and Purkinje cells of cerebellum [6].
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2. Duffy antigens
There are six known antigens with four main phenotypes; Fy(a+b+), Fy(a−b+), 
Fy(a+b−), and Fy(a−b−) (Table 1) [5]. The most common antigens are, two poly-
morphic and antithetical, Fya (FY1) and Fyb (FY2) which differ by one amino acid 
at position 42 on the extracellular domain, with glycine resulting in Fya expression 
and aspartic acid resulting in Fyb expression [5, 7]. They are sensitive to destruction 
when RBCs are treated with proteolytic enzymes such as papain or ficin, whereas, 
there is no RBCs destruction with trypsin treatment [8].
Fya antigen has a prevalence of 66% in Caucasians, 10% in Blacks, and 99% in 
Asians. It has been identified on fetal RBCs as early as 6 weeks gestation and reaches 
adult levels in approximately 12 weeks after birth. Fyb has a prevalence of 83% in 
Caucasians, 23% in Blacks, and 18.5% in Asians. It is expressed on cord blood cells. Fy3 
antigen is expressed in 100% of Caucasians, 32% of Blacks, and 99.9% of Asians. It is 
also expressed on cord cells and demonstrates increased expression after birth. Fy5 
antigen is expressed on 32% of Blacks and 99.9% of Caucasians and Asians. It is not 
expressed on Rh null RBCs. Fy6 is expressed in 100% of most populations and 32% of 
Blacks. The Fy(a–b–) phenotype is the major phenotype in approximately 70% Blacks, 
but is very rarely found in other populations. This phenotype is characterized by the 
Figure 1. 
The predicted seven-transmembrane domain structure of the Duffy protein. The amino acid change responsible 
for Fya/Fyb polymorphism, the mutation responsible for Fyx, and the glycosylation sites and the regions where 
Fy3 (and Fy6) map are indicated (reproduced with permission).
Red cell phenotype Prevalence (%) Allele
Caucasians Blacks
Fy (a+b−) 17 9 FY*01/FY*01 or FY*A/FY*A
Fy (a−b+) 34 22 FY*02/FY*02 or FY*B/FY*B
Fy (a+b+) 49 1 FY*A/FY*B
Fy (a−b−) Rare 68 FY*/N.01–05, FY*/N.01–02‡
Fy3 100 32
Fy5 99.9 32
Fy6 100 32
‡Nomenclature pending approval by the ISBT working party on terminology for red cell surface antigens.
Table 1. 
Duffy blood group system phenotypes and prevalence. Reproduced with permission and modification.
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absence of the Fyb antigen on RBCs and its presence on non-erythroid cells. Duffy 
mRNA is not detected in the bone marrow of Fy(a–b–) individuals; however, it is 
detected in other tissues including the colon, lung, and spleen. This unique phenotype 
is caused by a single amino acid substitution at position 46 in the Duffy (Fyb) gene. 
This mutation impairs the promotor activity in erythroid cells by disrupting the binding 
site for GATA1 erythroid transcription factor. Furthermore, some individuals with this 
phenotype do not make anti-Fyb. This is believed to be due to a mutation in the, ery-
throid promoter, GATA-1 binding motif. Interestingly, the same Fy(a–b–) phenotype 
rarely found in Caucasians is characterized by absence of Duffy antigens expression in 
both erythroid and non-erythroid tissues due to possibly presence of mutations which 
prevent formation of Duffy protein. These individuals can form anti-Fy3. The have 
high prevalence antigens; Fy3, Fy5, and Fy6 are conformational epitopes as opposed 
to specific sequence epitopes with Fy5 hypothesized to be a combined conformational 
epitope of Duffy and Rh protein. [9–12].
3. Duffy antibodies
Anti-Fya and -Fyb are clinically significant RBC alloantibodies which can cause 
immediate and delayed hemolytic transfusion reactions (HTRs) as well as hemolytic 
disease of the fetus and newborn (HDFN). They often result from previous exposure 
such as after transfusion or pregnancy. They are not usually naturally occurring. The 
Duffy antibodies are predominantly of the IgG subclass whereas the IgM form is rare.
The mechanism of extravascular hemolysis (EH) in both HDFN and HTR is 
similar. In HDFN, the mother lacks a certain red cell antigen which the fetus is 
positive for, thus the mother is allo-immunized (i.e., made a new antibody) during 
the first pregnancy. If she gets exposed to the same antigen in subsequent pregnancy 
(ies), the fetus (es) is/are at risk of HDFN. Similarly, if a patient lacks a certain red 
cell antigen but receives red cell transfusion with a unit that has such antigen, the 
patient is at risk for allo-immunziation after the transfusion and HTR in subsequent 
transfusion (s). EH is typically induced by IgG red cell antibodies. EH consists of 
consumption of antibody and/or C3b-bound red cells by phagocytes in the reticulo-
endothelial system (RES) causing a delayed hemolytic transfusion reaction (DHTR). 
DHTRs can be clinically significant leading to morbidity and possibly mortality. To 
avoid DHTR, patients with known clinically significant antibodies, receive red cell 
units that lack antigen (s) to their the cognate antibody (ies). The Duffy antibodies 
are usually associated with a moderate DHTR and mild HDFN [13].
Anti-Fya is identified more than anti-Fy3, anti-Fy5, or anti-Fyb. Fya is 20 times 
more immunogenic than Fyb. Some of anti-Fya can bind and activate complements 
[14]. Anti-Fy3 is also clinically significant antibody which can cause mild HDFN and 
HTRs. Serologically, it can react with enzyme treated Fy(a+) or Fy(b+) RBCs, but 
fails to react with Fy(a−b−) RBCs [15]. Anti-Fy4 shows lack of consistent test results. 
It was found to be reactive with Fy(a−b−), some Fy(a+b−), some Fy(a−b+) RBCs 
but shows no reaction with Fy(a+b+) RBCs [16]. Anti-Fy5 reacts with enzyme treated 
Fy(a+) or Fy(b+) RBCs with no reaction with Fy(a−b−) RBCs or Rh null RBCS. It has 
been reported in sickle cell patients with delayed HTRs in the presence of other clini-
cally significant alloantibodies [17]. A human anti-Fy6 has not been identified [18].
4. The Duffy glycoprotein as a receptor for chemokines
The Duffy glycoprotein can bind to a variety of chemokines and is known 
commonly as the Duffy antigen receptor for chemokines (DARC) or more recently 
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atypical chemokine receptor 1 (ACKR1). Chemokines are proteins secreted by 
immune cells as a mean to communicate signals to guide their interactions. The 
exact function of DARC is not fully clear. One postulated function is that DARC 
permits erythrocyte to act a chemokine scavenger to limit leukocyte activation. The 
importance of this function in inflammatory diseases is not well established [6, 19].
5. Duffy and malaria
The Duffy glycoprotein plays an important role in malaria transmission by 
acting as the erythroid receptor for Plasmodium vivax through binding to the 
Fy6 epitope (previously known as P. vivax Duffy-binding protein (PvDbp)) and 
for Plasmodium knowlesi. Individuals with Fy(a−b−) phenotype were resistant 
to parasitic invasion in a study performed on 11 volunteers, whereas those who 
contracted malaria were Fy(a+) or Fy(b+). Fy6 is present on all erythroid cells with 
an Fy(a+) or Fy(b+) phenotype. Thus it is absent on red cells with Fy(a−b−) phe-
notype. In west Africa, individuals with Fy(a−b−) phenotype are found in greater 
frequency than in areas where P. vivax is absent. The protective effect of Fy(a−b−) 
phenotype does not extend to P. falciparum which can infect red cells of all Duffy 
phenotype [20].
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